Table 1 Characteristics of the patients
SexAge(years)ANCA-VStatusChronology PF-ANCA-VFollow-up (months)ClinicalType of PFTLC/TLCO at diagnosis(%)IAHMPO-ANCAsEosinophils(×109/l)PF aggra-vationRelapse of ANCA-V
1F78MPADead: CMV pneumoniaSame time7L KNSIP0113
2M71MPADead: vasculitisPF preceded ANCA-V7L KND01ND
3M77MPADead: exacerbation of ESRFSame time60L NND81/46011.1YesYes
4M71MPADead: exacerbation of ESRFSame time37L N S MUIP71/72010.8YesNo
5M69MPADead: exacerbation of ESRFSame time67L K N SUIP74/46011.2YesYes
6F64MPAAliveSame time52L NUIP101/87010.6YesNo
7M69MPAAliveSame time92L K MUIP78/62014.4YesNo
8M70MPAAlivePF preceded ANCA-V18L K N MUIP010.5NoYes
9M64MPAAlivePF after ANCA-V109E L K S OND010.2NoYes
10F75WGAliveSame time54LND01NDNoNo
11M67MPAAlivePF preceded ANCA-V116L K M NUIP45/5101<0.1NoNo
12M73WGAliveSame time63E L K HND010.2NoNo
  • ANCA-V, systemic vasculitis related to antineutrophil cytoplasmic antibodies; CMV, cytomegalovirus; E, ear–nose–throat; ESRF, end-stage respiratory failure; IAH, intra-alveolar haemorrhage; K, kidney; L, lung; M, muscles; MPA, microscopic polyangiitis; MPO-ANCAs, anti-myeloperoxidase-ANCAs; N, neuropathy; ND, not determined; NSIP, non-specific interstitial pneumonia; O, ophthalmology; PF, pulmonary fibrosis; S, skin; TLC, total lung capacity at diagnosis (%); TLCO, carbon monoxide transfer factor; UIP, usual interstitial pneumonia; WG, Wegener’s granulomatosis.